Showing 4351-4360 of 8792 results for "".
- Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Developmenthttps://practicaldermatology.com/news/sirnaomics-appoints-dr-francois-lebel-as-senior-vice-president-for-preclinical-and-clinical-development/2461896/Dr. Francois Lebel, M.D is the new Senior Vice President for preclinical and clinical development at Sirnaomics Ltd. "With multiple drug candidates moving into clinical studies, including two clinical trials advancing to late-stage development, Sirnaomics is embarkin
- Practical Dermatology® Unveils New Cover Redesign for July 2023 Issuehttps://practicaldermatology.com/news/practical-dermatology-unveils-new-cover-redesign-for-july-2023-issue/2461895/Bryn Mawr Communications, publisher of Practical Dermatology®, has announced a captivating new cover redesign for the magazine, which will debut with their upcoming July issue. This visual update signals the first of many changes coming to the publication. "We are thrilled to unveil our s
- Research Validates Atopic March Patternhttps://practicaldermatology.com/news/research-validates-the-atopic-march/2461889/New research validates a population-level pattern of the “allergic march” in which allergies first present as eczema, followed by food allergies, asthma, and environmental allergies. The average peak age of onset was approximately four months for eczema, 13 months
- Low Vitamin D Status Linked to PsO Severityhttps://practicaldermatology.com/news/low-vitamin-d-status-linked-to-pso-severity-2/2461887/Vitamin D levels may play a role in psoriasis severity, according to one of the largest studies to date. The analysis, which included almost 500 psoriasis cases from the National Health and Nutrition Examination Survey (NHANES), showed a linear relationship between increasing psoriasis
- FDA Approves Verrica Pharmaceuticals’ YCANTH for Molluscum Contagiosumhttps://practicaldermatology.com/news/fda-approves-verrica-pharmaceuticals-ycanth-for-molluscum-contagiosum/2461882/The U.S. Food and Drug Administration (FDA) has given its nod to Verrica Pharmaceuticals Inc.’s YCANTH (cantharidin) topical solution for the treatment of molluscum contagiosum in adult and pediatric patients aged two and older. "It's the only topical FDA-approved therapy
- First AD Patient Dosed in Lynk Pharmaceuticals' Phase Ib Clinical Study of Topical JAK Inhibitorhttps://practicaldermatology.com/news/first-ad-patient-dosed-in-lynk-pharmaceuticals-phase-ib-clinical-study-of-topical-jak-inhibitor/2461881/The first atopic dermatitis (AD) patient has been dosed in a Phase Ib clinical trial of LNK01004, Lynk Pharmaceuticals Co., Ltd. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LNK01004 ointment in Chinese patient
- ASA’s SPOTS Program Wins an International Award for Social Responsibility in Dermatologyhttps://practicaldermatology.com/news/asas-spots-program-wins-an-international-award-for-social-responsibility-in-dermatology/2461880/The American Skin Association (ASA)’s SPOTS (Sun Protection Outreach Teaching by Students) program was selected as one of five "Top Projects" in North America by the International Awards for Social Responsibility in Dermatology. The awards are a partnersh
- LRP Celebrates Acne Positivity with Two-Day 'Positivity Lab' Pop-Up Experience in NYChttps://practicaldermatology.com/news/lrp-celebrates-acne-positivity-with-two-day-positivity-lab-pop-up-experience-in-nyc/2461879/La Roche-Posay is hosting a consumer pop-up experience to help destigmatize acne. The pop-up will feature an immersive "Science of Skin" exhibit, a meditation lounge in partnership with obé Fitness, Doodle Bar with custom art done by local artists, and a Positivity Phot
- Enspectra Health Awarded NIH Grant to Advance Predictive Algorithms for AKshttps://practicaldermatology.com/news/enspectra-health-awarded-nih-grant-to-advance-predictive-algorithms-for-aks/2461874/Enspectra Health scored $2M in grant funding from the National Cancer Institute (NCI) to support research for developing deep learning algorithms to predict which actinic keratosis (AK) lesions, are likely to progress to squamous cell carcinoma (SCC). Enspectra's technolog
- Hoth Therapeutics Receives Protocol Approval for HT-001https://practicaldermatology.com/news/hoth-therapeutics-receives-protocol-approval-for-ht-001/2461873/Hoth Therapeutics, Inc. received approval from the Food & Drug Administration (FDA) for a protocol change in its Phase 2a clinical trial of HT-001. Participants will apply HT-001 Gel once per day for six weeks, during which the effect on treating acneiform rash and other skin